Monopar Therapeutics (MNPR) Net Cash Flow (2017 - 2025)

Monopar Therapeutics has reported Net Cash Flow for 9 years, with the latest figure at -$65.9 million in Q4 2025.

• Quarterly Net Cash Flow fell 265.69% year-over-year to -$65.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.9 million (down 58.7% YoY) and the FY2025 annual result came in at $15.9 million, down 58.7% from the prior year.
• Net Cash Flow retreated to -$65.9 million in Q4 2025 per MNPR's latest filing, from $88.2 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $88.2 million in Q3 2025 and troughed at -$65.9 million in Q4 2025.
• A 5-year average of $2.3 million and a median of -$1.6 million in 2021 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2021 and 2025: Net Cash Flow tumbled 2814.45% in 2021, then surged 84636.59% in 2025.
• Over 5 years, Net Cash Flow stood at -$2.0 million in 2021, then tumbled by 198.16% to -$6.1 million in 2022, then jumped by 128.92% to $1.8 million in 2023, then soared by 2162.54% to $39.8 million in 2024, then sank by 265.69% to -$65.9 million in 2025.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$65.9 million, $88.2 million, and -$206922.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.